• BiondVax Receives Additional Grant Funding americanpharmaceuticalreview
    August 21, 2017
    BiondVax Pharmaceuticals announced the Israel Innovation Authority (IIA) agreed to fund up to 40% of a NIS 2.7 million (approximately US$ 750,000) budget towards ongoing development of M-001, the company's Universal Flu Vaccine candidate.
PharmaSources Customer Service